Related references
Note: Only part of the references are listed.The role of peroxisome proliferator-activated receptor gamma in prostate cancer
Catherine Elix et al.
ASIAN JOURNAL OF ANDROLOGY (2018)
The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity
Saghar Yousefnia et al.
GENE (2018)
Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5
Lianyue Guan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway
Jie Ni et al.
EXPERIMENTAL CELL RESEARCH (2017)
Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer
Wanli Yang et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1
P. Phatak et al.
ONCOGENE (2016)
PPAR gamma as a Novel Therapeutic Target in Lung Cancer
Aravind T. Reddy et al.
PPAR RESEARCH (2016)
Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression
Daniela Rovito et al.
ONCOTARGET (2016)
Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4
Aamir Ahmad et al.
BMC CANCER (2015)
microRNA miR-10b inhibition reduces cell proliferation and promotes apoptosis in non-small cell lung cancer (NSCLC) cells
Junchao Huang et al.
MOLECULAR BIOSYSTEMS (2015)
被撤回的出版物: miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin (Retracted article. See vol. 47, pg. 54, 2022)
Hang Tian et al.
ONCOLOGY REPORTS (2015)
Small Molecule Agonists of PPAR-γ Exert Therapeutic Effects in Esophageal Cancer
Hiroshi Sawayama et al.
CANCER RESEARCH (2014)
Aberrant Regulation and Function of MicroRNAs in Cancer
Brian D. Adams et al.
CURRENT BIOLOGY (2014)
Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer
Ramesh Singh et al.
MOLECULAR CANCER (2014)
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Jiri Polivka et al.
PHARMACOLOGY & THERAPEUTICS (2014)
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines
Richard Hummel et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Friend or foe: the role of microRNA in chemotherapy resistance
Haoran Li et al.
ACTA PHARMACOLOGICA SINICA (2013)
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists
Kenneth K. W. To et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Howard A. Burris
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer
San-Jian Yu et al.
CLINICAL CANCER RESEARCH (2013)
MicroRNAs as therapeutic targets in chemoresistance
Michela Garofalo et al.
DRUG RESISTANCE UPDATES (2013)
PPARγ against Tumors by Different Signaling Pathways
Zhi Zhang et al.
ONKOLOGIE (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Treatments for esophageal cancer: a review
Hiroyuki Kato et al.
GENERAL THORACIC AND CARDIOVASCULAR SURGERY (2013)
MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells
Naohiro Nishida et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
K. Hirashima et al.
BRITISH JOURNAL OF CANCER (2012)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma
Kotaro Hirashima et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth
Naohiko Hamaguchi et al.
CANCER SCIENCE (2010)
MicroRNA-10b Promotes Migration and Invasion through KLF4 in Human Esophageal Cancer Cell Lines
Yanyan Tian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway
Liang-qi Cao et al.
ACTA PHARMACOLOGICA SINICA (2009)
Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats
Kulbhushan Tikoo et al.
BMC CANCER (2009)
Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
D. Chen et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway
Sungha Park et al.
YONSEI MEDICAL JOURNAL (2008)
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway
Ling-Zhi Liu et al.
CANCER RESEARCH (2007)
PI3K/Akt signalling pathway and cancer
JAF Vara et al.
CANCER TREATMENT REVIEWS (2004)
Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells
JT Lee et al.
CANCER RESEARCH (2004)
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
S Chan
BRITISH JOURNAL OF CANCER (2004)
Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer
Y Terashita et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
